BEMA Buprenorphine To Proceed To Phase 2 Following Favorable Initial Study Results
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced preliminary results from a Phase 1 study assessing two new formulations of the opioid analgesic buprenorphine utilizing the company’s proprietary BEMA? drug delivery technology. The study was performed to select the optimal formulation for Phase 2 clinical development of the product candidate, known as BEMA? Buprenorphine.
More: continued here
Filed under: Pain / Anesthetics on March 31st, 2009
You must be logged in to post a comment.